Immune Thrombocytopenic Purpura (ITP) As a Complication of COVID-19: A Case Report
,
Abstract
Immune thrombocytopenic purpura (ITP) is a condition that can occur either spontaneously or as a secondary complication of preexisting disorders, often associated with viral infections. In the context of COVID-19, hematological manifestations, including thrombocytopenia, have been observed and linked to increased mortality rates among severely infected patients.Presented here is a case study of a 70-year-old man who recovered from COVID-19 but subsequently developed ITP. The severity of his thrombocytopenia exceeded what is typically observed during COVID-19 infections, leading to a diagnosis of ITP. Treatment with steroids and intravenous immunoglobulin (IVIG) was initiated based on specialist recommendations, resulting in an adequate response.
[1]Bhattacharjee S, Banerjee M, Pal R. COVID-19 associated hemophagocytic lymphohistiocytosis and coagulopathy:
targeting the duumvirate. Indian Pediatr. 2020;57:827-33. https://doi.org/10.1007/s13312-020-1962-z
[2]Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Zhong N. Clinical characteristics of coronavirus disease. 2019:1708-20.
[3]Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020;2:2048-58. https://doi.org/10.1007/s42399-020-00521-8
[4]Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. https://doi.org/10.1182/ blood-2008-07-162503
[5]Bomhof G, Mutsaers PG, Leebeek FW, Te Boekhorst PA, Hofland J, Croles FN, et al. COVID-19-associated immune
thrombocytopenia. Br J Haematol. 2020;190(2):e61. https:// doi.org/10.1111/bjh.16850
[6]Yonal-Hindilerden I, Kart-Yasar K, Sevtap S, Hindilerden F. Immune Thrombocytopenia in a Very Elderly Patient With Covid-19.
[7]Humbert S, Razanamahery J, Payet-Revest C, Bouiller K, Chirouze C. COVID-19 as a cause of immune thrombocytopenia. Med Mal Infect. 2020;50(5):459-60. https://doi.org/10.1016/j. medmal.2020.05.003
[8]McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and
defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163 75.https://doi.org/10.1016/j.hoc.2009.08.008
[9]Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S. Evans syndrome in a patient with COVID-19. Br J Haematol.
2020;190(2):e59. https://doi.org/10.1111/bjh.16846
[10]Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-30. https://doi.org/10.1056/ NEJMoa2104882
[11]Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22- year-old post Covid-19 vaccine. Am J Hematol. 2021;96(5):E133. https://doi.org/10.1002/ajh.26106
[12]Revuz S, Vernier N, Saadi L, Campagne J, Poussing S, Maurier F. Immune thrombocytopenic purpura in patients with COVID-19. Eur J Case Rep Intern Med. 2020;7(7).
[13]Sun L, Wang J, Shao L, Yuan C, Zhao H, Li D, et al. Dexamethasone plus oseltamivir versus
dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2021;8(4):e289-e98. https://doi.org/10.1016/ S2352-3026(21)00030-2
[14] Mahévas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management and
outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4):e224-e9. https://doi.org/10.1111/bjh.17024
targeting the duumvirate. Indian Pediatr. 2020;57:827-33. https://doi.org/10.1007/s13312-020-1962-z
[2]Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Zhong N. Clinical characteristics of coronavirus disease. 2019:1708-20.
[3]Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020;2:2048-58. https://doi.org/10.1007/s42399-020-00521-8
[4]Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. https://doi.org/10.1182/ blood-2008-07-162503
[5]Bomhof G, Mutsaers PG, Leebeek FW, Te Boekhorst PA, Hofland J, Croles FN, et al. COVID-19-associated immune
thrombocytopenia. Br J Haematol. 2020;190(2):e61. https:// doi.org/10.1111/bjh.16850
[6]Yonal-Hindilerden I, Kart-Yasar K, Sevtap S, Hindilerden F. Immune Thrombocytopenia in a Very Elderly Patient With Covid-19.
[7]Humbert S, Razanamahery J, Payet-Revest C, Bouiller K, Chirouze C. COVID-19 as a cause of immune thrombocytopenia. Med Mal Infect. 2020;50(5):459-60. https://doi.org/10.1016/j. medmal.2020.05.003
[8]McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and
defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163 75.https://doi.org/10.1016/j.hoc.2009.08.008
[9]Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S. Evans syndrome in a patient with COVID-19. Br J Haematol.
2020;190(2):e59. https://doi.org/10.1111/bjh.16846
[10]Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-30. https://doi.org/10.1056/ NEJMoa2104882
[11]Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22- year-old post Covid-19 vaccine. Am J Hematol. 2021;96(5):E133. https://doi.org/10.1002/ajh.26106
[12]Revuz S, Vernier N, Saadi L, Campagne J, Poussing S, Maurier F. Immune thrombocytopenic purpura in patients with COVID-19. Eur J Case Rep Intern Med. 2020;7(7).
[13]Sun L, Wang J, Shao L, Yuan C, Zhao H, Li D, et al. Dexamethasone plus oseltamivir versus
dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2021;8(4):e289-e98. https://doi.org/10.1016/ S2352-3026(21)00030-2
[14] Mahévas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management and
outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4):e224-e9. https://doi.org/10.1111/bjh.17024
| Files | ||
| Issue | Vol 8 No 4 (2023): July-August | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/crcp.v8i4.14571 | |
| Keywords | ||
| Immune hrombocytopenic purpura Covid-19 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ashraf Talesh shaghayegh, Hadadi A. Immune Thrombocytopenic Purpura (ITP) As a Complication of COVID-19: A Case Report. CRCP. 2024;8(4):143-145.
